Dr. DeJesus is a graduate from the University of Puerto Rico, School of Medicine. He completed his Internal Medicine training and Infectious Disease fellowship at the Medical College of Pennsylvania in Philadelphia and is board certified in Infectious Diseases. He has been a fellow of the American College of Physicians since 1996.
Dr. DeJesus is the medical director for the Orlando Immunology Center (OIC) in downtown Orlando and maintains a secondary office with Infectious Disease Consultants (IDC) in Altamonte Springs, Fla.
Since 1993, Dr. DeJesus has devoted most of his time to caring for HIV and hepatitis-infected patients. He is also deeply involved in HIV-related research: He is the principal investigator for the OIC Research Facility, where he oversees several phase 1-4 clinical trials. In this capacity, he has presented study results at major international conferences such as the International AIDS Conference, International AIDS Society Conference, Interscience Conference on Antimicrobial Agents and Chemotherapy, and the Conference on Retroviruses and Opportunistic Infections.
Dr. DeJesus has remained highly active in Florida's Hispanic HIV community, where he has implemented and supported educational, preventative and research programs. He has participated as a guest speaker for community programs, medical forums and as part of the HIV and infectious diseases training of physicians in medical centers around the country.
Edwin DeJesus, M.D., F.A.C.P., has received research support from Abbott Laboratories, Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Hoffman LaRoche Laboratories, Merck, Pfizer, Schering Plough, Taimed, Tobira, Tibotec and Vertex. He has been a consultant and received honorarium from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Tibotec and Vertex Pharmaceuticals. He has served on speakers bureaus for Gilead Sciences, Merck, Tibotec and Virco.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.